Zeria Pharmaceutical Co Ltd
TSE:4559
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
Biotechnology
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
3M Co
NYSE:MMM
|
Industrial Conglomerates
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Realty Income Corp
NYSE:O
|
Real Estate
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Walt Disney Co
NYSE:DIS
|
Media
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
This note will be permanently deleted.
Zeria Pharmaceutical Co Ltd
Zeria Pharmaceutical Co Ltd
Cash Equivalents
Zeria Pharmaceutical Co Ltd
Cash Equivalents Peer Comparison
4502
4568
4578
4519
4503
Competitive Cash Equivalents Analysis
Latest Figures & CAGR of Competitors
| Company | Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
|
|
Zeria Pharmaceutical Co Ltd
TSE:4559
|
Cash Equivalents
¥20.3B
|
CAGR 3-Years
28%
|
CAGR 5-Years
20%
|
CAGR 10-Years
-1%
|
|
|
Takeda Pharmaceutical Co Ltd
TSE:4502
|
Cash Equivalents
¥457.8B
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-4%
|
|
|
Daiichi Sankyo Co Ltd
TSE:4568
|
Cash Equivalents
¥647.2B
|
CAGR 3-Years
19%
|
CAGR 5-Years
22%
|
CAGR 10-Years
13%
|
|
|
Otsuka Holdings Co Ltd
TSE:4578
|
Cash Equivalents
¥411.6B
|
CAGR 3-Years
1%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-1%
|
|
|
Chugai Pharmaceutical Co Ltd
TSE:4519
|
Cash Equivalents
¥462.9B
|
CAGR 3-Years
42%
|
CAGR 5-Years
30%
|
CAGR 10-Years
15%
|
|
|
Astellas Pharma Inc
TSE:4503
|
Cash Equivalents
¥335.7B
|
CAGR 3-Years
1%
|
CAGR 5-Years
2%
|
CAGR 10-Years
-2%
|
See Also
What is Zeria Pharmaceutical Co Ltd's Cash Equivalents?
Cash Equivalents
20.3B
JPY
Based on the financial report for Mar 31, 2024, Zeria Pharmaceutical Co Ltd's Cash Equivalents amounts to 20.3B JPY.
What is Zeria Pharmaceutical Co Ltd's Cash Equivalents growth rate?
Cash Equivalents CAGR 10Y
-1%
Over the last year, the Cash Equivalents growth was 25%. The average annual Cash Equivalents growth rates for Zeria Pharmaceutical Co Ltd have been 28% over the past three years , 20% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet
